Role of Microparticles in Covid-19 Infection

Completed

• Conditions: COVID-19
• Interventions: Other: Blood sample

• Registration Number: NCT04448743
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Among the distinctive features of Covid-19, numerous reports have stressed the importance of vascular damages associated with coagulopathy onset. Microparticles (MPs) shed by apoptotic/stimulated cells are reliable markers of vascular damage released upon pro-inflammatory conditions and behave as active participants in the early steps of clot formation. In addition, MPs carry ACE1 and ACE2, the cell-entry receptor for SARS-Cov2 in the vasculature and up-regulate ACE1 expression in neighbouring endothelial cells. This may contribute to unopposed angiotensin II accumulation which further exacerbate tissue injury and promote both inflammation and thrombosis. The aim of the study is to evaluate the impact of circulating MPs on ACE2 expression, the cell-entry receptor for SARS-Cov2 on endothelial cells.

Detailed Description

Circulating MPs will be isolated from Covid-19 patients with lupus anticoagulant, from coronary artery diseases patients and from healthy volunteers without cardiovascular risk factors. Quantification of MPs will be realized by prothrombinase assay. Primary endothelial cells (ECs) from porcine coronary artery or porcine pulmonary artery will be isolated and cultured. ECs will be exposed to circulating MPs. Phenotypical changes (ACE2 expression, cytoadhesins, cytokines, tissue factor expression) of ECs will be examined. Susceptibility of ECs to SARS-COV-2 infection will be determined.

Study Timeline

• Study First Submitted: 2020-06-22
• Study First Submitted QC: 2020-06-25
• Study First Posted: 2020-06-26
• Study Start: 2020-07-02
• Primary Completion: 2021-10-04
• Study Completion: 2021-10-04
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-15
• Last Update Posted: 2022-06-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 189

Inclusion Criteria

• COVID-19 patients: age > 18 yr
• SARS-COV-2 infection within 12 months and positive lupus anticoagulant
• Patients with cardiovascular risk factors: at least among
• Hypertension, Dyslipidemia, Diabetes mellitus, obesity, smoker, Healthy volunteers

Exclusion Criteria

• Significant comorbidities (active cancer, auto-immune diseases...)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
healthy volunteers	Blood sample	-
Covid-19 patients	Blood sample	-
patients with coronary artery disease	Blood sample	-

Primary Outcome Measures

Name	Time	Method
Western blot measurement of ACE2 receptor expression in porcine cells	Through study completion, an average of 1 year

Trial Locations

Locations (1)

Olivier MOREL; 🇫🇷 Strasbourg, France